CD274 and cancer: The use of immune checkpoint (IC) blockade strategies, e.g. against programmed death-1 receptor (PD-1), PD-1’s ligand (PD-L1), and cytotoxic lymphocyte antigen-4 (CTLA4) is expanding in cancer immunotherapy1.